Are We Overstating the Risk of Priapism with Oral Phosphodiesterase Type 5 Inhibitors?. Issue 8 (2nd July 2020)

• Record Type: Journal Article
• Authors: Rezaee, Michael E.; Gross, Martin S.
• Is Part Of: Journal of sexual medicine. Volume 17:Issue 8(2020)
• Page Start: 1579
• Page End: 1582
• Publication Date: 2020-07-02
• Subjects: Erectile Dysfunction -- Priapism -- PDE5 Inhibitors -- Men's Health; Sexual disorders -- Periodicals; Sex -- Periodicals; Sexual health -- Periodicals; 616.69005
• DOI: 10.1016/j.jsxm.2020.05.019
• Languages: English
• ISSNs: 1743-6095

Abstract

Abstract: Background: Priapism is an adverse drug reaction (ADR) associated with phosphodiesterase type 5 inhibitors (PDE5is) in the treatment of erectile dysfunction. Aim: The purpose of this study was to identify the true data about PDE5i-associated priapism to properly counsel patients. Methods: We queried the U.S. Food and Drug Administration (FDA) Adverse Reporting System Public Dashboard to identify cases of drug-induced priapism among medications commonly associated with priapism. Next, a systematic review and analysis of publications describing cases of drug-induced priapism were carried out. Outcomes: The main outome of this study is incidence of PDE5i-induced priapism. Results: We found 411 cases of drug-induced priapism secondary to Viagra, Cialis, or Levitra reported to the Food and Drug Administration since 1998. Compared with PDE5is, drug-induced priapism was 2.6 (n = 1, 065) and 2.0 times (n = 817) more commonly reported for second-generation antipsychotics and the antidepressant/sleep aid trazodone, respectively. A total of 240 manuscripts describing cases of drug-induced priapism in patients with non-sickle cell disease were identified. PDE5i-induced priapism accounted for only 2.9% (n = 7) of drug-induced priapism cases. Second-generation antipsychotics (33.8%), a group of "other" medications (11.3%), and alpha-adrenergic antagonists (8.8%) accounted for the greatest percentage of published drug-induced priapism cases. Clinical Implications: Extensive counseling about priapism as an ADR for PDE5i for the routine treatment of erectile dysfunction is likely unnecessary. Strengths & Limitations: The study used national-level data to identify drug-induced priapism cases. Reported and published cases of drug-induced priapism may reflect more severe and atypical cases of this ADR, which may have underestimated our results. Conclusion: PDE5i-induced priapism is a rare event. Drug-induced priapism should be attributed to a wider spectrum of medications that can cause this condition.